April 19th 2024
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Epigenetic Biomarker Predicts Resistance to CAR T-Cell Therapy in ALL
April 12th 2022Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.
Read More
T-Cell Attributes of Axi-cel Correlate With Outcomes in Large B-Cell Lymphoma
April 11th 2022CCR7-positive and CD45RA-positive T cells that expressed CD27 and CD28 appear to be associated with all efficacy metrics, including durability or response, according to an analysis of the ZUMA-7 clinical trial.
Read More
GD2-Directed CAR T Cells Shows Durable Benefit in H3K27M+ Diffuse Intrinsic Pontine Gliomas
April 10th 2022Prolonged periods of radiographic and clinical improvement in children and young adults with H3K27M diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas has been shown with GD2-directed chimeric antigen receptor T cells.
Read More
Non-Response to Blinatumomab Shows Significant Association With Worse Survival Outcomes in B-ALL
April 6th 2022In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.
Read More
FDA Approves Second-Line Axi-Cel for Adults With LBCL
April 1st 2022The FDA has granted approval to axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, according to an announcement from the FDA.
Read More
Phase 1b/2 Study To Evaluate AUTO1 CAR T Cells in Relapsed/Refractory Adult B-Cell ALL
March 29th 2022Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Read More
CARCIK-CD19 Protocol Provides Lymphodepleted Patients Access to CAR T-cell Treatment in B-ALL
March 24th 2022Chimeric antigen receptor T cells manufactured using the Sleeping Beauty transposon in donor-derived cells and differentiated toward the cytokine-induced killer cell protocol induce a sustained response with minimal toxicities in patients with B-cell acute lymphoblastic leukemia.
Read More
CAR T-Cell Use Possible in Metastatic Castration-Resistant Prostate Cancer
March 7th 2022In an interview with Targeted Oncology, Tanya Dorff, MD, discussed the exploration of chimeric antigen receptor T-cell therapy in prostate cancer, including recent findings from a phase 1 clinical trial.
Read More
Considerations When Selecting Patients With R/R Myeloma for Cilta-Cel Treatment
March 4th 2022Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.
Watch
Behind the FDA Approval: Cilta-cel for Treatment of Heavily Pretreated R/R Multiple Myeloma
March 3rd 2022In an interview, Jesus Berdeja, MD, discussed the introduction of ciltacabtagene autoleucel into the treatment landscape for relapsed/refractory multiple myeloma, how it may differ from idecabtagene vicleucel, and the future of CAR T-cell use in the space.
Read More
FDA Grants Priority Review to Liso-Cel for Adults With Relapsed/Refractory LBCL
February 17th 2022The FDA will conduct a speedy review of the supplemental biologics license application for lisocabtagene maraleucel as second-line treatment for adult patients with relapsed or refractory large B-cell lymphoma.
Read More